(TheNewswire)
LONDON, ONTARIO – TheNewswire - February 3, 202 1 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a leadingclinical-stage regenerative medicine therapeutics company, is pleasedto announce that Dr. Sam Wiseman, BSc, MD, FRCSC, FACS of theUniversity of British Columbia and co-investigator of Sernova’s CellPouch Hypothyroid treatment program will present preclinical data inan oral presentation at the American Association of Endocrine Surgeons(AAES) 2021 Annual Meeting taking place April 25-27, 2021. Dr. SamWiseman, Professor, Richard J. Finley Scholar, andDirector of Research at the Department of Surgery of Providence HealthCare also serves as Chair of the Endocrine Tumor Group for theSurgical Oncology Network in Vancouver British Columbia.
Dr. Wiseman’s abstract was selected amongst over 140 abstracts foran Oral Podium Presentation and a resulting journal article will bepeer-reviewed for publication consideration in the journal Surgery.
For more information on the American Association of Endocrine Surgeonsand the 41 st AnnualMeeting, visit https://meeting.endocrinesurgery.org/ .
ABOUT SERNOVA’S HYPOTHYROID PROGRAM
Sernova’s initial approach in treating hypothyroid disease is totransplant a patient’s own healthy thyroid tissue followingthyroidectomy into the pre-implanted vascularized Cell Pouch torecover the normal function of the thyroid gland. In collaborationwith Dr. Wiseman, preclinical proof of concept work is being conductedunder a grant from the British Columbia Transplant Foundation.Following successful completion of preclinical studies, Sernova plansto conduct clinical assessments of the Cell Pouch with transplantedthyroid tissue in patients suffering from hypothyroid disease with theaim to preserve thyroid function and improve patient quality of life.
Thyroidectomy is commonly performed for cancer diagnosis or treatmentand for treatment of benign (non-cancerous) disease that includesgoiter and hyperthyroidism. It is estimated that about 150,000thyroidectomies are performed in the US yearly, and the majority ofindividuals undergoing a thyroid operation are diagnosed with benigndiseases after their procedure. Patients with Grave’s disease andthyroid nodules undergoing total thyroidectomy, and many patientsundergoing partial thyroidectomy require life-long thyroid hormonemedication. Post-surgical thyroid hormone replacement therapy, ifmonitored carefully, can be effective; however, patients often sufferfrom deleterious side-effects including weight gain, depression,headaches, and cardiovascular disease, with resultant negative impacton quality of life, and significant costs to the healthcare system. The development of new therapeutic strategies to overcomehypothyroidism remains an important unmet medical need.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutictechnologies using a medical device and immune protected therapeuticcells (i.e. human donor cells, corrected human cells, and stemcell-derived cells) to improve the treatment and quality of life ofpeople with chronic metabolic diseases such as insulin-dependentdiabetes, hypothyroidism, hemophilia, and other diseases treatedthrough replacement of proteins or hormones missing or in short supplywithin the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
Copyright (c) 2021 TheNewswire - All rights reserved.